Diagnosis of an increased serum level of ferritin;Démarche diagnostique devant une hyperferritinémie

Revue de Medecine Interne

Volumn 36, Issue 8, 2015, Pages 522-529

  Lorcerie, B ^a   Audia, S ^a   Samson, M ^a   Milliere A ^a   Falvo, N ^a   Leguy Seguin, V ^a   Berthier, S ^a   Bonnotte, B ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

Alcoholism; Cytolysis; Hepatic MRI; Hereditary hemochromatosis; Hyperferritinemia; Inflammatory syndrome; Metabolic syndrome

Indexed keywords

FERRITIN; IRON;

ALCOHOLISM; CYTOLYSIS; FERRITIN BLOOD LEVEL; HEMATOLOGIC DISEASE; HEMOCHROMATOSIS; HYPERFERRITINEMIA; INFLAMMATION; IRON OVERLOAD; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE IMAGING; SHORT SURVEY; BLOOD; COMPLICATION; HUMAN; IRON METABOLISM DISORDERS;

FERRITINS; HUMANS; IRON METABOLISM DISORDERS;

EID: 84937726719     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2014.12.007     Document Type: Short Survey

References (71)

1. Lieu P.T., Heiskala M., Peterson P.A., Yang Y. The roles of iron in health and disease. Mol Aspects Med 2001, 22:1-87.
2. Loréal O., Bardou-Jacquet E., Jouanolle A.M., Gandon Y., Deugnier Y., Brissot P., et al. Métabolisme du fer et outils diagnostiques pour le clinicien. Rev Med Interne 2012, 33:S3-S9.
3. Beaumont C., Karim Z. Actualité du métabolisme du fer. Rev Med Interne 2013, 34:17-25.
4. Pre J. La ferritine. Ann Med Interne 1989, 140:288-298.
5. Dezier J.F., Vernet M. Détermination de la ferritine sérique. Intérêt et limites. Presse Med 1992, 21:1283-1286.
6. Custer E.M., Finch C.A., Sobel R.E., Zettner A. Population norms for serum ferritin. J Lab Clin Med 1995, 126:88-94.
7. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276:7806-7810.
8. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001, 98:8780-8785.
9. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011, 117:4425-4433.
10. Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol 2011, 54:173-181.
11. Adams P.C., McLaren C.E., Speechley M., McLaren G.D., Barton J.C., Eckfeldt J.H. HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level <1000 microg/L. Can J Gastroenterol 2013, 27:390-392.
12. Le Page L., Leflon P., Mahevas M., Duhaut P., Smail A., Salle V., et al. Spectre étiologique des hyperferritinémies. Rev Med Interne 2005, 26:368-373.
13. Moirand R., Lescoat G., Delamaire D., Lauvin L., Campion J.P., Deugnier Y., et al. Increase in glycosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawal. Alcohol Clin Exp Res 1991, 15:963-969.
14. Bell H., Skinningsrud A., Raknerud N., Try K. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J Intern Med 1994, 236:315-322.
15. Adams P.C., Barton J.C. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol 2011, 55:453-458.
16. Brissot P., Le Lan C., Troadec M.B., Guillygomarc'h A., Lorho R., Jouanolle A.M., et al. Que faire devant une hyperferritinémie ? 2006, POST'U, Paris, www.fmcgastro.org.
17. Fleming R.E., Ponka P. Iron overload in human disease. N Engl J Med 2012, 366:348-359.
18. Lorcerie B., Bonnotte B., Chauffert B., Khardouche H., Aho S., Meynadier M., et al. Ferritine sérique et glycosylée dans les syndromes inflammatoires et les cancers. Rev Med Interne 1997, 18:490s.
19. Zandman-Goddard G., Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007, 6:457-463.
20. Di Bisceglie A.M., Axiotis C.A., Hoofnagle J.H., Bacon B.R. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992, 102:2108-2113.
21. Arber N., Konikoff F.M., Moshkowitz M., Baratz M., Hallak A., Santo M., et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994, 39:2656-2659.
22. Ferrara F., Ventura P., Vegetti A., Guido M., Abbati G., Corradini E., et al. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol 2009, 104:605-616.
23. Gono T., Katsumata Y., Kawaguchi Y. Idiopathic inflammatory myopathies from the viewpoint of rheumatologists. Brain Nerve 2013, 65:1275-1282.
24. Gono T., Miyake K., Kawaguchi Y., Kaneko H., Shinozaki M., Yamanaka H. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology 2012, 51:1336-1338.
25. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005, 366:1059-1062.
26. Moirand R., Mortaji A.M., Loréal O., Paillard F., Brissot P., Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997, 349:95-97.
27. Deugnier Y., Bonnot P., Lainé F. Hépatosidérose dysmétabolique. Hepatogastroenterology 2008, 15:19-24.
28. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999, 117:1155-1163.
29. Ruivard M., Laine F., Ganz T., Olbina G., Westerman M., Nemeth E., et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 2009, 50:1219-1225.
30. Bozzini C., Girelli D., Olivieri O., Martinelli N., Bassi A., De Matteis G., et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005, 28:2061-2063.
31. Gandon Y., Olivie D., Guyader D., Aube C., Oberti F., Sebille V., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004, 363:357-362.
32. Kowdley K.V., Belt P., Wilson L.A., Yeh M.M., Neuschwander-Tetri B.A., Chalasani N., et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012, 55:77-85.
33. Salonen J.T., Nyyssönen K., Korpela H., Tuomilehto J., Seppänen R., Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992, 86:803-811.
34. Esposito K., Chiodini P., Colao A., Lenzi A., Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012, 35:2402-2411.
35. Hursting S.D., Hursting M.J. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol 2012, 32(8):1766-1770.
36. Roblin X., Phelip J.M., Hilleret M.N., Heluwaert F., Bonaz B., Zarski J.P. Impact de la correction des facteurs de risque du syndrome métabolique sur l'hépatosidérose dysmétabolique. Gastroenterol Clin Biol 2003, 27:1079-1083.
37. Guillygomarc'h A., Mendler M.H., Moirand R., Laine F., Quentin V., David V., et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001, 35:344-349.
38. Rosmorduc O. Hémochromatose liée au gène HFE : de la génétique à l'expression clinique. Lett Hepatogastroenterol 2005, VIII:58-61.
39. Gasser B., Courtois F., Hojjat-Assari S., Sauleau E.A., Buffet C., Brissot P. [Hereditary hemochromatosis: presenting manifestations and diagnostic delay]. Rev Med Interne 2014, 35:160-165.
40. Wong K., Adams P.C. The diversity of liver diseases among outpatient referrals for an elevated serum ferritin. Can J Gastroenterol 2006, 20:467-470.
41. Olynyk J.K., Cullen D.J., Aquilia S., Rossi E., Summerville L., Powell L.W. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999, 341:718-724.
42. Knovich M.A., Storey J.A., Coffman L.G., Torti S.V., Torti F.M. Ferritin for the clinician. Blood Rev 2009, 23:95-104.
43. Alexander J., Kowdley K.V. HFE-associated hereditary hemochromatosis. Genet Med 2009, 11:307-313.
44. Guyader D., Jacquelinet C., Moirand R., Turlin B., Mendler M.H., Chaperon J., et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998, 115:929-936.
45. Beaton M., Guyader D., Deugnier Y., Moirand R., Chakrabarti S., Adams P. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 2002, 36:673-678.
46. Milman N., Pedersen P., á Steig T., Byg K.E., Graudal N., Fenger K. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 2001, 80:737-744.
47. Gochee P.A., Powell L.W., Cullen D.J., Du Sart D., Rossi E., Olynyk J.K. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002, 122:646-651.
48. Ryan Caballes F., Sendi H., Bonkovsky H.L. Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int 2012, 32:880-893.
49. Girelli D., Olivieri O., De Franceschi L., Corrocher R., Bergamaschi G., Cazzola M. A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. Br J Haematol 1995, 90:931-934.
50. Bonneau D., Winter-Fuseau I., Loiseau M.N., Amati P., Berthier M., Oriot D., et al. Bilateral cataract and high serum ferritin: a new dominant genetic disorder?. J Med Genet 1995, 32:778-779.
51. Arnold J.D., Mumford A.D., Lindsay J.O., Hegde U., Hagan M., Hawkins J.R. Hyperferritinaemia in the absence of iron overload. Gut 1997, 41:408-410.
52. Ferrante M., Geubel A.P., Fevery J., Marogy G., Horsmans Y., Nevens F. Hereditary hyperferritinaemia-cataract syndrome: a challenging diagnosis for the hepatogastroenterologist. Eur J Gastroenterol Hepatol 2005, 17:1247-1253.
53. Takamatsu J., Majima M., Miki K., Kuma K., Mozai T. Serum ferritin as a marker of thyroid hormone action on peripheral tissues. J Clin Endocrinol Metab 1985, 61(4):672-676.
54. Said R. L'hyperthyroïdie : une cause d'élévation de la ferritine sérique. Rev Med Interne 2000, 21:1129-1131.
55. Mekinian A., Stirnemann J., Belmatoug N., Heraoui D., Fantin B., Fain O., et al. Ferritinemia during type 1 Gaucher disease: mechanisms and progression under treatment. Blood Cells Mol Dis 2012, 49:53-57.
56. Stein P., Yu H., Jain D., Mistry P.K. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol 2010, 85:472-476.
57. Bohte A.E., van Dussen L., Akkerman E.M., Nederveen A.J., Sinkus R., Jansen P.L., et al. Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PloS One 2013, 8:e57507.
58. Stirnemann J., Boutten A., Vincent C., Mekinian A., Heraoui D., Fantin B., et al. Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease. Blood Cells Mol Dis 2011, 46:34-38.
59. Rose C. Surcharge en fer d'origine hématologique. Rev Med Int 2012, 33(Suppl 1):S15-S18.
60. Zanella A., Berzuini A., Colombo M.B., Guffanti A., Lecchi L., Poli F., et al. Iron status in red cell pyruvate kinase deficiency: study of Italian cases. Br J Haematol 1993, 83:485-490.
61. Pennell D.J. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci 2005, 1054:373-378.
62. Loréal O., Troadec M.B., Detivaud L., Brissot P. Actualités sur la physiopathologie des surcharges en fer. Lett Hepatogastroenterol 2005, VIII:54-57.
63. Brissot P., Le Lan C., Lorho R., Loréal O. Hémochromatoses non liées à l'HFE-1. Lett Hepatogastroenterol 2005, VIII:62-64.
64. Michot J.M., Hie M., Galicier L., Lambotte O., Michel M., Bloch-Queyrat C., et al. Le syndrome d'activation lymphohistiocytaire de l'adulte. Rev Med Interne 2013, 34:85-93.
65. Dhote R., Simon J., Papo T., Detournay B., Sailler L., Andre M.H., et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 2003, 49:633-639.
66. Pouchot J., Vinceneux P. Diagnostic, évolution et pronostic, pathogénie et traitement de la maladie de Still de l'adulte. Presse Med 2004, 33:1019-1026.
67. Vignes S., Le Moël G., Fautrel B., Wechsler B., Godeau P., Piette J.C. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still's disease. Ann Rheum Dis 2000, 59:347-350.
68. Rosario C., Zandman-Goddard G., Meyron-Holtz E.G., D'Cruz D.P., Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 2013, 11:185.
69. Agmon-Levin N., Rosario C., Katz B.S., Zandman-Goddard G., Meroni P., Cervera R., et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus 2013, 22:1327-1335.
70. Garcia P.C., Longhi F., Branco R.G., Piva J.P., Lacks D., Tasker R.C. Ferritin levels in children with severe sepsis and septic shock. Acta Paediatr 2007, 96:1829-1831.
71. Saglini V., Brissot P. Hyperferritinémie--Algorithme. Rev Med Suisse 2012, 8:1135-1137.